Skip to main content
Premium Trial:

Request an Annual Quote

DeCode CEO to Sell Up to 400,000 Shares in Next Year

NEW YORK, July 2 (GenomeWeb News) -Kari Stefansson, CEO of DeCode Genetics, will sell up to 400,000 shares of DeCode's common stock in the next year, or 12 percent of his holdings, under a pre-arranged plan that follows US Securities and Exchange Commission regulations, the company said today.


At today's share price, Stefansson would net about $3.4 million from the transactions.


Under the plan, Stefansson has authorized a broker to sell the shares on his behalf. The move is designed to diversify Stefansson's investments, according to the Reykjavik, Iceland-based company.


The sales are being made pursuant to rule 10b5-1 of the US Securities and Exchange Act of 1934, which allows company insiders to establish pre-arranged stock trading plans not based on inside information.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.